Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma - Poll - MDSpire

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

  • By

  • Leo Rasche

  • Maria Theresa Krauth

  • Hermine Agis

  • Christoph Renner

  • Irene Strassl

  • Raphael Teipel

  • Vladan Vučinić

  • Katja Weisel

  • Wolfgang Willenbacher

  • Marc S. Raab

  • May 13, 2026

  • 0 min

Share

Original Source(s)

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

  • by Leo Rasche, Maria Theresa Krauth, Hermine Agis, Christoph Renner, Irene Strassl, Raphael Teipel, Vladan Vučinić, Katja Weisel, Wolfgang Willenbacher, Marc S. Raab

  • May 13, 2026

Related Content

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma